UA105760C2 - Антитіло проти bst2 - Google Patents
Антитіло проти bst2Info
- Publication number
- UA105760C2 UA105760C2 UAA201005531A UAA201005531A UA105760C2 UA 105760 C2 UA105760 C2 UA 105760C2 UA A201005531 A UAA201005531 A UA A201005531A UA A201005531 A UAA201005531 A UA A201005531A UA 105760 C2 UA105760 C2 UA 105760C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibody
- bst2d
- bst2
- tissue
- specifically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Abstract
Винахід належить до антитіла проти BST2 людини, яке зв'язується з антигеном BST2D людини, що експресується з високими рівнями у ракових клітинах, але по суті не зв'язується з антигеном BST2H людини. Також запропоновано терапевтичні та діагностичні засоби, які включають антитіло цього винаходу, які специфічно виявляють тканини, що експресують BST2D.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007269470 | 2007-10-16 | ||
PCT/JP2008/068794 WO2009051201A1 (ja) | 2007-10-16 | 2008-10-16 | 抗bst2抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA105760C2 true UA105760C2 (uk) | 2014-06-25 |
Family
ID=40567462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201005531A UA105760C2 (uk) | 2007-10-16 | 2008-10-16 | Антитіло проти bst2 |
Country Status (15)
Country | Link |
---|---|
US (2) | US8529896B2 (uk) |
EP (1) | EP2210939A4 (uk) |
JP (1) | JP5558825B2 (uk) |
KR (1) | KR20100090258A (uk) |
CN (2) | CN104031150A (uk) |
AU (1) | AU2008312858A1 (uk) |
BR (1) | BRPI0817427A8 (uk) |
CA (1) | CA2702939A1 (uk) |
HK (1) | HK1153502A1 (uk) |
IL (1) | IL205073A (uk) |
MX (1) | MX2010004251A (uk) |
NZ (1) | NZ585394A (uk) |
RU (1) | RU2010119450A (uk) |
UA (1) | UA105760C2 (uk) |
WO (1) | WO2009051201A1 (uk) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
US9730941B2 (en) | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
WO2014066271A1 (en) * | 2012-10-22 | 2014-05-01 | Becton, Dickinson And Company | Non-b-lineage cells capable of producing antibody |
US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
NZ728688A (en) | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
RU2722212C9 (ru) * | 2014-08-05 | 2020-07-23 | СиБи ТЕРЕПЬЮТИКС, ИНК. | Анти-pd-l1 антитела |
US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
CN107619443B (zh) * | 2016-07-14 | 2020-08-14 | 深圳宾德生物技术有限公司 | 抗人和鼠cd317的单克隆抗体及其制备方法和应用 |
EP4168029A1 (en) * | 2020-06-19 | 2023-04-26 | Board of Regents, The University of Texas System | Anti-bst2 antibodies targeting bst2 long isoform |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US305121A (en) * | 1884-09-16 | Razor-strop | ||
ZA948016B (en) * | 1993-10-15 | 1995-05-31 | Toshio Hirano | A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof |
US6503510B2 (en) | 1997-02-12 | 2003-01-07 | Chugai Seiyaku Kabushiki Kaisha | Remedies for lymphocytic tumors |
ATE317900T1 (de) | 1998-02-25 | 2006-03-15 | Chugai Pharmaceutical Co Ltd | Für hm1.24 antigen kodierendes gen und dessen promotor |
JP4450555B2 (ja) * | 2000-12-28 | 2010-04-14 | 協和発酵キリン株式会社 | 新規モノクローナル抗体 |
EP1364657B1 (en) | 2001-02-07 | 2016-12-28 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myelocytic leukemia |
US7776612B2 (en) | 2001-04-13 | 2010-08-17 | Chugai Seiyaku Kabushiki Kaisha | Method of quantifying antigen expression |
US8603481B2 (en) | 2003-10-10 | 2013-12-10 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for solid tumors |
WO2006008886A1 (ja) | 2004-06-11 | 2006-01-26 | Ginkgo Biomedical Research Institute Co., Ltd. | インターフェロン産生細胞の活性調節剤 |
WO2006013923A1 (ja) * | 2004-08-05 | 2006-02-09 | Ginkgo Biomedical Research Institute Co., Ltd. | 自己免疫疾患を伴う関節炎の治療剤 |
JPWO2006054748A1 (ja) | 2004-11-22 | 2008-06-05 | Sbiバイオテック株式会社 | 腎炎の治療剤 |
US20080299128A1 (en) | 2006-06-20 | 2008-12-04 | Myung Kim | Effect of Bst2 on inflammation |
-
2008
- 2008-10-16 US US12/738,285 patent/US8529896B2/en not_active Expired - Fee Related
- 2008-10-16 JP JP2009538149A patent/JP5558825B2/ja not_active Expired - Fee Related
- 2008-10-16 AU AU2008312858A patent/AU2008312858A1/en not_active Abandoned
- 2008-10-16 BR BRPI0817427A patent/BRPI0817427A8/pt not_active IP Right Cessation
- 2008-10-16 WO PCT/JP2008/068794 patent/WO2009051201A1/ja active Application Filing
- 2008-10-16 RU RU2010119450/10A patent/RU2010119450A/ru unknown
- 2008-10-16 CN CN201410162825.3A patent/CN104031150A/zh active Pending
- 2008-10-16 KR KR1020107010635A patent/KR20100090258A/ko not_active Application Discontinuation
- 2008-10-16 NZ NZ585394A patent/NZ585394A/en not_active IP Right Cessation
- 2008-10-16 MX MX2010004251A patent/MX2010004251A/es active IP Right Grant
- 2008-10-16 UA UAA201005531A patent/UA105760C2/uk unknown
- 2008-10-16 EP EP08838804A patent/EP2210939A4/en not_active Withdrawn
- 2008-10-16 CA CA2702939A patent/CA2702939A1/en not_active Abandoned
- 2008-10-16 CN CN200880122043.XA patent/CN101952426B/zh not_active Expired - Fee Related
-
2010
- 2010-04-14 IL IL205073A patent/IL205073A/en not_active IP Right Cessation
-
2011
- 2011-07-18 HK HK11107441.7A patent/HK1153502A1/xx not_active IP Right Cessation
-
2013
- 2013-08-22 US US13/973,930 patent/US20130336967A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0817427A2 (pt) | 2015-06-16 |
KR20100090258A (ko) | 2010-08-13 |
RU2010119450A (ru) | 2011-11-27 |
IL205073A (en) | 2014-07-31 |
MX2010004251A (es) | 2010-08-30 |
US20130336967A1 (en) | 2013-12-19 |
EP2210939A4 (en) | 2012-08-08 |
WO2009051201A1 (ja) | 2009-04-23 |
BRPI0817427A8 (pt) | 2019-01-29 |
IL205073A0 (en) | 2010-11-30 |
AU2008312858A1 (en) | 2009-04-23 |
CN101952426B (zh) | 2014-04-16 |
JPWO2009051201A1 (ja) | 2011-03-03 |
CN104031150A (zh) | 2014-09-10 |
HK1153502A1 (en) | 2012-03-30 |
CN101952426A (zh) | 2011-01-19 |
JP5558825B2 (ja) | 2014-07-23 |
US8529896B2 (en) | 2013-09-10 |
US20100278832A1 (en) | 2010-11-04 |
CA2702939A1 (en) | 2009-04-23 |
EP2210939A1 (en) | 2010-07-28 |
NZ585394A (en) | 2012-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA105760C2 (uk) | Антитіло проти bst2 | |
WO2007109376A3 (en) | Anti-tumor cell antigen antibody therapeutics | |
NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
WO2010096434A3 (en) | Specific binding proteins and uses thereof | |
CY1115935T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
EA201190041A1 (ru) | Человеческие аутоантитела против альфа-синуклеина | |
NZ598194A (en) | Anti-cmet antibody and its use for the detection and the diagnosis of cancer | |
BR112013004266A2 (pt) | anticorpos anti-ox40 e métodos de uso dos mesmos. | |
CR20120506A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
IN2014CN03936A (uk) | ||
WO2011041319A8 (en) | Specific binding proteins and uses thereof | |
CA2749846A1 (en) | Methods of determining patient response by measurement of her-3 | |
EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
EA201071068A1 (ru) | Антитела к tyrp1 | |
TR201902972T4 (tr) | Kanseri tespit etmek için yöntem. | |
RU2012148816A (ru) | Метод диагностики для определения клеток ex vivo | |
WO2010031749A9 (en) | Compositions and methods for detecting tlr3 | |
RU2016102202A (ru) | Биологический маркер опухоли | |
WO2006083957A3 (en) | Tat-001 and methods of assessing and treating cancer | |
WO2012077983A3 (ko) | Ape1/ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트 | |
WO2006133145A3 (en) | Tat-007 and methods of assessing and treating cancer | |
WO2006116681A3 (en) | Tat-003 and methods of assessing and treating cancer | |
WO2007089793A3 (en) | Tat-041 and methods of assessing and treating cancer | |
WO2007089690A3 (en) | Tat-042 and methods of assessing and treating cancer |